The anti-malaria vaccinewill be put into production in less than 2 years due to successful investigations of British pharmaceutical company GlaxoSmithKline.
The majority of deaths occur among children living in Africa, where every minute a child dies from malaria. That is why the experimental vaccine RTS, S was grafted 16 thousand children in seven African countries.
“We’re very encouraged by these latest results, which show that RTS,S continued to provide meaningful protection over 18 months to babies and young children across different regions of Africa. While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive. These data support our decision to submit a regulatory application for the vaccine candidate which, if successful, would bring us a step closer to having an additional tool to fight this deadly disease. We are grateful to the scientists across Africa and GSK and to our partners who have worked tirelessly for almost 30 years to bring us to this point,” - Sir Andrew Witty, CEO of GSK, said.
The development of this vaccine is a major breakthrough in the fight against malaria. Prior to that, the main method of combating this disease has been covering homes with toxic insecticides, most of which are banned in many countries due to the negative impact on human health.
Author: Olga Broskova